Literature DB >> 11193206

The histogenesis of giant cell tumour of bone: a model of interaction between neoplastic cells and osteoclasts.

M H Zheng1, P Robbins, J Xu, L Huang, D J Wood, J M Papadimitriou.   

Abstract

Giant cell tumour of bone (GCT) is a benign primary neoplasm of a bone characterised by distinctive clinical, radiological and pathological features. Females are slightly more often affected than males, and the majority of patients present between the ages of 20 and 50. GCT is locally aggressive and produces expansive and lytic lesions, most commonly in the epiphyses of long tubular bones. Histologically, it is composed of oval and spindle mononuclear cells, uniformly distributed amongst which are large multinucleated osteoclast-like giant cells. Although the term "Giant Cell Tumour" (and the erroneous historical term 'osteoclastoma') may imply that it is the multinucleated giant cells which are responsible for the proliferative capacity of the tumour, there is evidence that the stromal-like cells, the major component of the mononuclear cell population, represent the true neoplastic component of the neoplasm. The diagnosis and management of conventional GCT are often challenging and there is considerable current interest in its pathobiology. The precise histogenesis of GCT and the nature of its varying cellular constituents have remained a matter of some controversy. Factors influencing the clinical course and biological aggression of GCT are also unclear. In this selective review, the clinicopathological characteristics of GCT are summarised and current areas of interest in the study of the neoplasm are presented and discussed. Lastly, a hypothetical model of the mechanism of histogenesis and the biological behaviour of GCT is presented.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11193206     DOI: 10.14670/HH-16.297

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  30 in total

Review 1.  Giant cell tumor of bone.

Authors:  Alan W Yasko
Journal:  Curr Oncol Rep       Date:  2002-11       Impact factor: 5.075

2.  Histogenetic characterization of giant cell tumor of bone.

Authors:  Manuela Salerno; Sofia Avnet; Marco Alberghini; Armando Giunti; Nicola Baldini
Journal:  Clin Orthop Relat Res       Date:  2008-06-10       Impact factor: 4.176

3.  The hypermetabolic giant: 18F-FDG avid giant cell tumor identified on PET-CT.

Authors:  Wendi O'Connor; Megan Quintana; Scott Smith; Monte Willis; Jordan Renner
Journal:  J Radiol Case Rep       Date:  2014-06-30

Review 4.  Giant cell tumor of bone: current treatment options.

Authors:  Keith M Skubitz
Journal:  Curr Treat Options Oncol       Date:  2014-09

5.  Histopathological, immunohistochemical, and image analytic parameters characterizing the stromal component in primary and recurrent giant cell tumor of bone.

Authors:  Charu Chandra Saxena; Rajni Safaya; Neha Kawatra Madan; Shah Alam Khan; Venkateswaran K Iyer
Journal:  J Clin Orthop Trauma       Date:  2015-10-26

Review 6.  Role of NADPH oxidase in formation and function of multinucleated giant cells.

Authors:  Mark T Quinn; Igor A Schepetkin
Journal:  J Innate Immun       Date:  2009-07-07       Impact factor: 7.349

7.  Giant cell tumor of temporomandibular joint masquerading as temporomandibular joint pain dysfunction syndrome: a rare case report.

Authors:  Jo Ee Sam; Rullyandrianto Pan Nuriman Rachmat; Cri Saiful Jordan Melano; Nasser Abdul Wahab
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2017-04-25

8.  Giant cell tumor of bone with secondary aneurysmal bone cyst.

Authors:  Chetan Anchan
Journal:  Int J Shoulder Surg       Date:  2008-07

9.  Giant cell tumor of bone: a neoplasm or a reactive condition?

Authors:  Anwar Ul Haque; Ambreen Moatasim
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

10.  Cathepsin K is the principal protease in giant cell tumor of bone.

Authors:  Jan H N Lindeman; Roeland Hanemaaijer; Adri Mulder; P D Sander Dijkstra; Károly Szuhai; Dieter Bromme; Jan H Verheijen; Pancras C W Hogendoorn
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.